Cariprazine
Active pharmaceutical substance formulated in Jan Aushadhi generic products for CNS, Nerve & Mental Health treatment.
🧴 Clinical Application
Take orally once daily with water, with or without food. Because of the prolonged half-life of its active metabolites, steady state is reached after several weeks; changes in dose will not be fully reflected in plasma for 1-2 weeks.
⚠️ Side Effects
Common: Akathisia, insomnia, weight gain, nausea, headache, dizziness, restlessness. Rare/Severe: Boxed warning: Mortality in elderly dementia patients; neuroleptic malignant syndrome, tardive dyskinesia, and late-onset adverse events due to metabolite accumulation.
🛡️ Safety Warnings
Boxed warning for elderly patients with dementia-related psychosis. Monitor closely for akathisia and restlessness during dose titration. Because drug and metabolites accumulate over weeks, observe patients for late adverse reactions.
Jan Aushadhi Products containing Cariprazine
Found 4 generic formulation(s) containing this active ingredient.
Cariprazine Capsules 1.5 mg
Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.
Cariprazine Capsules 3 mg
Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.
Cariprazine Capsules 4.5 mg
Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.
Cariprazine Capsules 6 mg
Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Cariprazine.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Cariprazine Capsules 1.5 mg | 10's | ₹50.63 | Carilift, Ciprazet | ₹102.67 | 51% Save |
| Cariprazine Capsules 3 mg | 10's | ₹81.56 | Carilift, Ciprazet | ₹167.15 | 51% Save |
| Cariprazine Capsules 4.5 mg | 10's | Under Process | N/A | N/A | N/A |
| Cariprazine Capsules 6 mg | 10's | Under Process | N/A | N/A | N/A |
Frequently Asked Questions (FAQ)
Get answers to common queries about Cariprazine generics.